rmc
9 rmc Stellenangebote in Österreich. Täglich aktualisierte Angebote.
-
Medical Science Liaison, Austria Premium
Vor 1 Woche
Vienna, Österreich Revolution Medicines VollzeitRevolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor;...
-
Senior Oncology Account Manager, Austria Premium
Vor 1 Woche
Vienna, Österreich Revolution Medicines Remote VollzeitRevolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor;...
-
Director, Market Access, Austria Premium
Vor 2 Wochen
Vienna, Österreich Revolution Medicines VollzeitRevolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor;...
-
Director, Commercial, Austria
Vor 4 Wochen
Vienna, Vienna, 9, Österreich Revolution Medicines Remote VollzeitRevolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor;...
-
Senior Oncology Account Manager, Austria
Vor 1 Monat
Wien, Wien, Österreich Revolution Medicines VollzeitRevolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective...
-
Medical Science Liaison, Austria
Vor 2 Monaten
Wien, Wien, Österreich Revolution Medicines VollzeitRevolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective...
-
Director, Commercial, Austria
Vor 2 Monaten
Wien, Wien, Österreich Revolution Medicines VollzeitRevolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective...
-
Director, Medical Affairs, Austria
Vor 2 Monaten
Wien, Wien, Österreich Revolution Medicines VollzeitRevolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective...
-
Director, Market Access, Austria
Vor 2 Monaten
Wien, Wien, Österreich Revolution Medicines VollzeitRevolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective...
